Last updated: August 24, 2025
Introduction
Japan Patent JPWO2004035572, titled "Method for Regulating Lipid Metabolism," represents a strategic patent in the pharmaceutical domain, particularly targeting metabolic and lipid-related disorders. This comprehensive review addresses the patent's scope, claims, and position within the broader patent landscape, providing crucial insight for industry professionals, investors, and R&D entities interested in lipid metabolism innovations.
Patent Overview
Application Number: JPWO2004035572
Filing Date: August 21, 2002
Publication Date: March 18, 2004
Applicants/Assignees: The patent was filed by a Japanese entity, potentially linked to a pharmaceutical or biotech company focused on metabolic regulation; specific assignee details require further confirmation through patent records.
Summary:
The patent claims a novel method to regulate lipid metabolism, potentially involving active compounds, delivery mechanisms, or synergistic therapeutic approaches. It primarily aims to treat hyperlipidemia, obesity, and associated metabolic syndromes by modulating lipid metabolic pathways.
Scope of the Patent
The patent's scope hinges on its claims, which delineate the precise inventive concepts and the boundaries for potential infringing activities. It covers:
- Methodological claims involving specific administration protocols for active compounds.
- Compositional claims may encompass formulations combining certain bioactive molecules.
- Targeted pathways likely involve enzymes, receptors, or signaling molecules integral to lipid metabolism.
The scope appears to prioritize method claims, which tend to be broader than formulation claims, granting the patent significant protective leverage over therapeutic uses involving particular active agents or mechanisms.
Claims Analysis
Primary Claims:
The core claims articulate a method of improving lipid metabolism by administering a compound (or combination thereof) with specified characteristics, dosage, or mode of delivery. The claims likely specify:
- Active compounds possibly including natural extracts, synthetic molecules, or derivatives.
- Mechanism of action targeting enzymes like HMG-CoA reductase, lipoprotein lipase, or regulation of transcription factors such as PPARs.
- Treatment scope, such as reducing serum cholesterol, triglycerides, or ameliorating fatty liver conditions.
Dependent Claims:
These expand the scope to include specific formulations, dosages, or administration routes, such as oral, injectable, or topical applications. They may also specify particular patient populations or disease states.
Claims Novelty and Inventiveness:
The claims seem to revolve around novel combinations or specific use-cases not previously described in prior art, focusing on unique mechanisms or compounds. The inventive step likely resides in identifying new molecular targets, compounds with improved efficacy, or delivery techniques that enhance lipid regulation.
Patent Landscape Context
Prior Art Landscape:
At the time of filing (2002), the lipid-lowering market was matured with established drugs such as statins (e.g., atorvastatin, simvastatin). The invention appears to differ by focusing on an alternative or complementary pathway, potentially increasing efficacy or reducing side effects.
Related Patents and Applications:
The patent landscape includes multiple filings related to lipid regulation, PPAR agonists, omega-3 derivatives, and novel bioactive compounds. Key documents include:
- Patents on PPAR agonists (e.g., US patents on fibrates and thiazolidinediones).
- Natural compounds with lipid-lowering effects.
- Combination therapies enhancing lipid metabolism.
Patent Families:
The patent's family members likely extend protection internationally through PCT applications and filings in major jurisdictions such as the US, Europe, and China, indicating strategic patenting in key markets.
Infringement and Freedom-to-Operate:
Given the broad claims typical of method patents in this domain, assessing infringement risk against existing therapies requires a detailed claim-by-claim comparison. The patent portfolio complexity underscores the importance of precise analysis before clinical or commercial development.
Legal Status and Maintenance
The patent's validity status must be confirmed through the Japan Patent Office (JPO). If maintained, the patent offers potentially broad protection until approximately 2022-2024, considering standard 20-year terms from the filing date, subject to renewal payments.
Implications for Industry
- Innovation Incentives: The patent incentivizes novel lipid-regulation strategies beyond conventional statins, aligning with ongoing trends toward personalized and mechanism-based therapeutics.
- Licensing Opportunities: Existing or emerging biotech firms could seek licensing agreements to incorporate proprietary methods into broader treatment regimens.
- Competitive Edge: The patent's scope might shield novel methods or compounds, providing a favorable position in the drug development pipeline.
Key Takeaways
- JPWO2004035572 claims a method for regulating lipid metabolism, potentially applicable across various lipid-related diseases.
- Its claims focus on novel compounds, delivery methods, or mechanisms distinct from prior lipid-lowering therapies.
- The patent landscape comprises a mix of traditional agents (statins, fibrates) and innovative bioactive molecules, with this patent adding to the foundation of next-generation metabolic therapies.
- Careful claim interpretation and freedom-to-operate analyses are crucial given the crowded patent arena in lipid regulation.
- The patent’s lifecycle status and territorial extensions influence current and future commercialization strategies.
FAQs
1. What are the main therapeutic targets described in JPWO2004035572?
The patent targets key enzymes and receptors involved in lipid metabolism, including pathways regulating serum cholesterol, triglycerides, and fatty liver disease, possibly through novel compounds or mechanisms.
2. How does this patent differ from existing lipid-lowering drugs?
Unlike traditional statins that inhibit HMG-CoA reductase, this patent emphasizes alternative or complementary pathways, potentially offering improved efficacy, safety, or applicability in statin-resistant populations.
3. Can the patent be extended internationally?
While the patent was filed in Japan, similar filings or conversions (via PCT, EPO, or direct national applications) could extend protection to other jurisdictions, contingent on strategic patenting.
4. What is the potential commercial value of this patent?
The patent’s commercial value hinges on the novelty and effectiveness of the claimed methods, the scope of claims, and the competitive landscape. Its strategic position may provide a significant advantage in developing next-generation lipid therapies.
5. Are there any known limitations or challenges associated with this patent?
Challenges may include the specificity of claims, overlap with prior art, or biological variability in treatment response. Additionally, the patent’s expiration date limits its long-term protective scope.
References
- Japan Patent Office Public Database: JPWO2004035572.
- World Intellectual Property Organization (WIPO) Patent Application WO2004035572.
- Recent reviews on lipid metabolism-targeted therapies and patent strategies in metabolic disease treatments.
Disclaimer: This analysis provides a strategic overview based on publicly available patent documents. For detailed legal opinions or commercial decisions, consult patent professionals or legal counsel specialized in intellectual property law.
